SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Clin Mol Hepatol. 2023;29(3):779-793.

Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study.

, , , , , , , , , , , ,

제1저자 이창훈, 최광현 · 교신저자 정숙향, 김인희

소속 (10)
  1. Department of Internal Medicine, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea.
  2. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  3. Cancer Control and Population Health, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
  4. Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu, Korea.
  5. Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
  6. Department of Internal Medicine, Institute for Digestive Research, Digestive Disease Center, Soonchunhyang University College of Medicine, Seoul, Korea.
  7. Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
  8. Department of Internal Medicine, Yonsei University College of Medicine, Yonsei Liver Center, Severance Hospital, Seoul, Korea.
  9. Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Seoul, Korea.
  10. College of Pharmacy, Sahmyook University, Seoul, Korea.

Abstract

BACKGROUND/AIMS To eliminate hepatitis B virus (HBV) and hepatitis C virus (HCV) according to the World Health Organization (WHO) criteria in 2021, this study investigated the national core indicators representing the current status of viral hepatitis B and C in South Korea.

METHODS We analyzed the incidence, linkage-to-care, treatment, and mortality rates of HBV and HCV infection using the integrated nationwide big data of South Korea.

RESULTS According to data from 2018-2020, the incidence of acute HBV infection in South Korea was 0.71 cases per 100,000 population; tthe linkage-to-care rate was only 39.4%. Among those who need hepatitis B treatment, the treatment rate was 67.3%, which was less than 80% reported in the WHO program index. The annual liver-related mortality due to HBV was 18.85 cases per 100,000 population, exceeding the WHO target of four; the most frequent cause of death was liver cancer (54.1%). The annual incidence of newly diagnosed HCV infection was 11.9 cases per 100,000 population, which was higher than the WHO impact target of five. Among HCV-infected patients, the linkage-to-care rate was 65.5% while the treatment rate was 56.8%, which were below the targets of 90% and 80%, respectively. The liver-related annual mortality rate due to HCV infection was 2.02 cases per 100,000 population.

CONCLUSION Many of the current indicators identified in the Korean population did not satisfy the WHO criteria for validation of viral hepatitis elimination. Hence, a comprehensive national strategy should be urgently developed with continuous monitoring of the targets in South Korea.

Keywords

Diagnostic screening programsHepatitis BHepatitis CIncidenceMortality

Figures

Figure 1.
Figure 1. Incidence of hepatitis B and C virus infection according to age and sex. (A) Acute hepatitis B virus infection incidence in 2018–2020. This was analyzed by linking the national health insurance claims data between 2002 and 2020 based on the data of patients diagnosed with acute hepatitis B between 2018 and 2020 reported to the KDCA, excluding the data of those with two or more claims for acute hepatitis B within the 10-year wash-out period. (B) Incidence of newly detected hepatitis C virus infection in 2018–2020. This was analyzed by linking the national health insurance claims data between 2002 and 2020 based on the data of patients diagnosed with acute hepatitis C between 2018 and 2020 reported to the KDCA, excluding the data of those with two or more claims for hepatitis C virus infection within the 10-year wash-out period. KDCA, Korea Disease Control and Prevention Agency.
Figure 2.
Figure 2. Cascade of care for hepatitis B and C virus infection. (A) Hepatitis B. (B) Hepatitis C. HCV, hepatitis C virus; HBsAg, hepatitis B virus surface antigen. *The number of newly diagnosed HCV infections represents the annual average for the 2018–2020 period.

그림 출처: PubMed Central 공개 논문 (PMC10366799)

Comment · 정정

Conflict of interest statement

Conflicts of Interest . The authors have no conflicts to disclose.

그 밖의 정보
출판 형태
Journal Article
저널
Clinical and molecular hepatology · eISSN 2287-285X
전자 출판
2023-05-15
MeSH
Humans · Hepatitis B* / diagnosis / epidemiology / complications · Hepatitis C* / diagnosis / epidemiology · Liver Neoplasms* · Hepatitis, Viral, Human* · Hepacivirus · Republic of Korea / epidemiology · Hepatitis B virus
연구비
Korea Disease Control and Prevention Agency 20211214EC3-00 · Korea Disease Control and Prevention Agency 2020-E5104-02 · National Research Foundation of Korea · Ministry of Science, ICT and Future Planning 2021R1C1C1003181
참고문헌
46편